Common side effects associated with the use of<unk>  include: diarrhoea, nausea, rash, urticaria, pain and inflammation at injection site, superinfection (including candidiasis), allergy, and transient increases in liver enzymes and bilirubin. Rarely, in less than 1 in 1,000 people, cholestatic jaundice (also referred to as cholestatic hepatitis) has been associated with<unk>  therapy. It may appear as pale stool with dark urine, and yellowish eyes and skin. The reaction may occur up to several weeks after treatment has stopped, and takes weeks to resolve. The estimated incidence is one in 15,000 exposures, and is more frequent in people over the age of 55, females, and those with a treatment duration of longer than two weeks.<unk>  is contraindicated in those with a previous history of allergy to penicillins, cephalosporins, or carbapenems. It should also not be used in the eye, or administered to those with a history of cholestatic hepatitis associated with the use of dicloxacillin or<unk> . It should be used with caution in the elderly, patients with renal impairment where a reduced dose is required, and those with hepatic impairment, due to the risk of cholestatic hepatitis. It should be taken on an empty stomach, one half to one hour before food, as absorption is reduced when taken with food, though some studies suggest that this does not compromise<unk>  plasma concentrations in most circumstances. The UK's National Health Service recommends taking at least 30 minutes before food or at least 2 hours after. Drug interactions<unk>  can reduce the excretion of methotrexate, potentially resulting in a risk of methotrexate toxicity. The level of<unk>  in the blood may rise in kidney failure and with the use of probenecid.
Flucloxacillin
Piperacillin
Cloxacillin
Dicloxacillin
Resistin
Vancomycin
Cefazolin
Spiramycin